Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation

(2008) Michael D Oberst et al.   BMC CANCER

Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics

(2008) P. Sini et al.   CANCER RESEARCH

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

(2008) G Kroemer et al.   CELL DEATH AND DIFFERENTIATION

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

(2008) M. F. Press et al.   CLINICAL CANCER RESEARCH

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

(2008) R. Bianco et al.   CLINICAL CANCER RESEARCH

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

(2008) Guru Sonpavde et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

(2008) Anna Maria Storniolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non–Small-Cell Lung Cancer

(2008) Gregory J. Riely et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†

(2008) Philip A. Harris et al.   JOURNAL OF MEDICINAL CHEMISTRY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

The p53 family and programmed cell death

(2008) E C Pietsch et al.   ONCOGENE

Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment

(2008) Stefan Sleijfer et al.   Nature clinical practice. Oncology

Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer

(2008) David A Cameron et al.   Nature clinical practice. Oncology